Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The recently developed European Society for Radiotherapy and Oncology (ESTRO)/European Organization for Research and Treatment of Cancer (EORTC) oligometastatic disease (OMD) classification has not been validated in terms of its prognostic significance. This study stratified patients from the phase II SABR-5 trial based on ESTRO/EORTC criteria and compared progression-free survival (PFS) and overall survival (OS) to determine the prognostic significance of the classification scheme.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Int J Radiat Oncol Biol Phys

Title: International journal of radiation oncology, biology, physics

Publisher: Elsevier BV

ISSN (Electronic): 1879-355X

ISSN (Print): 0360-3016

Publication date (Electronic): Dec 01 2022

Volume: 114

Issue: 5

Affiliations

[1 ] Departement of Cancer, University of British Columbia, British Columbia, Canada; Departement of Cancer, University of British Columbia, BC Cancer - Surrey, British Columbia, Canada.

[2 ] Departement of Cancer, University of British Columbia, British Columbia, Canada; Departement of Cancer, University of British Columbia, BC Cancer - Kelowna, British Columbia, Canada.

[3 ] Departement of Cancer, University of British Columbia, British Columbia, Canada; Departement of Cancer, University of British Columbia, BC Cancer - Vancouver, British Columbia, Canada.

[4 ] Departement of Cancer, University of British Columbia, BC Cancer - Vancouver, British Columbia, Canada.

[5 ] Departement of Cancer, University of British Columbia, British Columbia, Canada; Departement of Cancer, University of British Columbia, BC Cancer - Victoria, British Columbia, Canada.

[6 ] Departement of Cancer, University of British Columbia, BC Cancer - Prince George, British Columbia, Canada.

[7 ] Departement of Cancer, University of British Columbia, British Columbia, Canada; Departement of Cancer, University of British Columbia, BC Cancer - Prince George, British Columbia, Canada. Electronic address: rolson2@bccancer.bc.ca.

Article

Publisher Item ID: S0360-3016(22)03129-7

DOI: 10.1016/j.ijrobp.2022.08.026

PubMed ID: 36302495

SO-VID: 5c7f2486-42f4-4ccb-8279-bcee6188fa52

History

Data availability:

Comments

Comment on this article

scite_

Cited by 6

See all cited by